Skip to main content
Almirall S.A. logo

Almirall S.A. — Investor Relations & Filings

Ticker · ALM ISIN · ES0157097017 LEI · 95980020140005007996 MC Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2021-11-01 Regulatory Filings
Country ES Spain
Listing MC ALM

About Almirall S.A.

http://www.almirall.com

Almirall S.A. is a global biopharmaceutical company specializing in medical dermatology. The company focuses on the research, development, manufacturing, and commercialization of proprietary medicines to address significant unmet needs in skin health. Leveraging scientific innovation, Almirall provides medical solutions designed to improve the well-being and quality of life for patients. Its operations encompass in-house research and development, strategic partnerships, and in-licensing to expand its portfolio of dermatological treatments.

Recent filings

Filing Released Lang Actions
AstraZeneca transfiere los derechos globales de Eklira y Duaklir a Covis Pharma.
Regulatory Filings Classification · 95% confidence The document is very short (985 characters) and announces a specific corporate transaction: AstraZeneca transferring global rights for two drugs (Eklira and Duaklir) to Covis Pharma, which impacts Almirall (ALM.MC) via existing milestone and royalty payments. This is a material event announcement that does not fit the specific categories like 10-K, ER, or IR. It relates to corporate activity and strategic changes, but the most fitting general category for a significant, non-standard corporate announcement that isn't a standard financial report or management change is 'Regulatory Filings' (RNS), as it is filed under Spanish securities law ('Ley del Mercado de Valores'). It is not a Director's Dealing, M&A (it's a divestiture/transfer of rights), or Capital Change. Given the nature of reporting material, non-standard corporate news, RNS is the appropriate fallback.
2021-11-01 Spanish
Operaciones del contrato de liquidez durante el tercer trimestre de 2021
Transaction in Own Shares Classification · 98% confidence The document is a formal announcement dated October 5, 2021, from Almirall, S.A., titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information), addressed to the CNMV (Comisión Nacional del Mercado de Valores - the Spanish securities market regulator). The content details the operations (purchases and sales of shares) conducted under a pre-existing liquidity contract (share buyback/stabilization agreement) during the third quarter of 2021 (July 1 to September 30, 2021). This type of filing, reporting transactions in the company's own shares, specifically relates to share repurchase programs. According to the definitions, 'Transaction in Own Shares' (Code: POS) covers reports of the company buying back or selling its own shares (share repurchase/issuance). The detailed tables confirm this is a report of executed transactions, not just an announcement of a report.
2021-10-05 Spanish
Almirall, S.A. ha procedido al cierre y desembolso de su emisión de obligaciones, por un importe nominal agregado de 300 millones de euros, con un tipo de interés fijo anual del 2,125 % y con vencimie
Capital/Financing Update Classification · 99% confidence The document is a formal communication dated September 22, 2021, issued under Spanish securities law (Ley del Mercado de Valores). The content explicitly announces the 'cierre y desembolso' (closing and disbursement) of a senior notes issuance totaling 300 million euros. This action relates directly to the company's fundraising and capital structure activities (issuance of debt securities). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an earnings release, an annual report, or a general regulatory filing (RNS), as it concerns a specific financing event.
2021-09-22 Spanish
Almirall ha completado con éxito la fijación del precio de su emisión de senior notes, por un importe de 300 millones de euros y con vencimiento en 2026
Capital/Financing Update Classification · 99% confidence The document is a formal notification in Spanish, dated September 15, 2021, announcing that Almirall, S.A. has successfully priced the issuance of senior notes (Obligaciones) totaling 300 million euros, maturing in 2026. It details the interest rate (2.125%), the intended use of the funds (to amortize existing convertible notes), and the credit ratings received from S&P and Moody's. This content directly relates to the company's fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an earnings release, an annual report, or a general regulatory filing (RNS), as it concerns a specific financing event.
2021-09-15 Spanish
Almirall, S.A. ha acordado llevar a cabo una emisión de obligaciones simples de rango sénior (senior notes), por un importe nominal agregado máximo de 250 millones de euros y con vencimiento en 2026
Capital/Financing Update Classification · 99% confidence The document text is an official notification from Almirall, S.A. dated September 13, 2021, disclosing that the company has agreed to issue senior notes (obligations) up to a maximum nominal amount of 250 million euros. This action involves fundraising, debt issuance, and capital structure modification. The content explicitly details the purpose of the funds (to repay existing convertible notes) and the terms of the offering (governed by New York law, offered under Rule 144A and Regulation S, and intended for listing on the Luxembourg Stock Exchange). This clearly falls under the category of updates on company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (over 10,000 characters), confirming it is the primary disclosure, not just an announcement of a report (RPA/RNS).
2021-09-13 Spanish
Lebrikizumab mejoró significativamente el aclaramiento de la piel y el picor en personas con dermatitis atópica de moderada a grave en dos ensayos de fase 3
Earnings Release Classification · 99% confidence The document is a formal announcement dated August 16, 2021, from Almirall, S.A., labeled as "OTRA INFORMACIÓN RELEVANTE" (Other Relevant Information) and explicitly states it is made "en cumplimiento de lo dispuesto en la Ley del Mercado de Valores" (in compliance with the Securities Market Law). The content details the positive top-line results of Phase 3 clinical trials (ADvocate 1 and ADvocate 2) for the drug Lebrikizumab. This structure—a formal announcement of significant, non-periodic business/clinical development news required by market regulators—is characteristic of a general regulatory filing or press release intended for immediate public disclosure. Since it is not a full Annual Report (10-K), a specific financial release (ER), or a proxy statement, and it is a direct announcement of material information rather than just an announcement *about* a report (RPA), the most appropriate classification is Regulatory Filing (RNS), which serves as the general category for such required disclosures that don't fit elsewhere. The document ends by stating, "A continuación adjuntamos la nota de prensa enviada a los medios de comunicación" (Attached below is the press release sent to the media), confirming its nature as a regulatory disclosure/press release. FY 2021
2021-08-16 Spanish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.